AstraZeneca Reports Successful Trials for Imfinzi and Enhertu Cancer Drugs
By Joe Hoppe
AstraZeneca PLC said Friday that new trial results show its
Imfinzi and Enhertu products improved survivability rates in cancer
The U.K. drug maker said that its Imfinzi treatment for small
cell lung cancer shows a sustained overall survival benefit in its
phase 3 trial, while its Enhertu treatment for gastric cancer
showed an improved tumor response rate, and improved overall
survival in its phase 2 trial.
AstraZeneca said that 11% of patients on Imfinzi and
chemotherapy had not had their cancer progress after two years and
remained on treatment at home, compared to 2.9% of patients who
stayed on chemotherapy alone. The company said that patients
treated with Imfinzi and chemotherapy maintained a 25% lower risk
of death than those on chemotherapy alone.
The second phase of the Enhertu trial showed an overall survival
improvement for previously treated metastatic gastric cancer, with
a 41% reduction in the risk of death on Enhertu compared to those
on chemotherapy, AstraZeneca said. The trial showed an overall
median survival of 12.5 months on Enhertu compared to 8.4 months on
chemotherapy, the company said, while tumor response rates on
Enhertu rose to 42.9% from 12.5% on chemotherapy.
Shares at 1226 GMT were up 225 pence, or 3%, at 8923 pence.
Write to Joe Hoppe at firstname.lastname@example.org
(END) Dow Jones Newswires
May 29, 2020 08:52 ET (12:52 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.